Kessler Topaz Meltzer & Check, LLP: Investor Class Action Filed Against Immunomedics, Inc. for Securities Fraud Violations
Company Name: Immunomedics, Inc.
Court: District of New Jersey
Case Number: 18-cv-17645
Judge: The Hon. Madeline Cox Arleo
Class period: between February 9, 2018 and January 17, 2019
Security Type: Common stock

Case Background:

On December 27, 2018, the initial complaint in this securities class action was filed against Immunomedics, Inc. (“Immunomedics”), and certain of Immunomedics’s directors and officers, asserting violations of sections 10(b) and 20(a) of the Securities Exchange Act.  

The complaint alleged that during the class period, the defendants made false and/or misleading statements, as well as failed to disclose material adverse facts. During the class period, and unbeknownst to investors, Immunomedics misled investors by stating in its United States Securities and Exchange Commission filings beginning on August 23, 2018, that, "the FDA generally will issue a notice on Form 483 if it finds issues with respect to its inspections" without disclosing to investors the fact that between August 6, 2018, and August 14, 2018 the FDA cited Immunomedics for a host of violations observed at its Morris Plains, New Jersey drug substance manufacturing facility. These violations included manipulated bioburden samples, misrepresentation of an integrity test procedure in the batch record, and backdating of batch records, such as dates of analytical results.

This is a federal securities class action brought on behalf of a class of those who purchased or otherwise acquired Immunomedics common stock between February 9, 2018 and January 17, 2019, inclusive.

Current Status of Case:

The lead plaintiffs filed a consolidated complaint on November 18, 2019. The defendants filed a motion to dismiss the consolidated complaint on January 17, 2020. On July 31, 2020, the Court denied the defendants' motion to dismiss, thereby allowing the action to proceed.  The parties are currently in the discovery phase of the litigation.  This action is still ongoing.

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP:  James Maro, Esq. (484-270-1453) or Adrienne Bell, Esq. (484-270-1435); toll-free at (844) 887-9500; or via e-mail at  If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.

Please complete this form relating to your transactions for Immunomedics, Inc. (Nasdaq: IMMU) common stock between February 8, 2018 and January 18, 2019, inclusive (the “Class Period”).

You may also contact James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435 or toll free at (844) 887-9500, or you may submit your information via email at, or you may click here to print a PDF of this form.

* Denotes required field
# of Shares
Price per Share
Principal Amount
Amount Paid
Series or CUSIP
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Immunomedics, Inc. (2019) prior to the Class Period?
Are you a current or former employee of Immunomedics, Inc. (2019)?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC
I would like to receive
new case alerts by email